[1] VAN DRIEL W J, KOOLE S N, SIKORSKA K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer[J].N Engl J Med,2018,378(3):230-240. [2] LHEUREUX S, BRAUNSTEIN M, OZA A M. Epithelial ovarian cancer: Evolution of management in the era of precision medicine[J].CA Cancer J Clin,2019,69(4):280-304. [3] DEL CAMPO J M, MATULONIS U A, MALANDER S, et al. Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the engot-ov16/nova trial[J].J Clin Oncol,2019,37(32):2968-2973. [4] COLEMAN R L, SPIRTOS N M, ENSERRO D, et al. Secondary surgical cytoreduction for recurrent ovarian cancer[J].N Engl J Med,2019,381(20):1929-1939. [5] 李彦磊,梁华,姜玉华,等.贝伐单抗联合化疗在非小细胞肺癌恶性胸腔积液患者中的应用效果[J].中国肿瘤临床与康复,2018,25(2):150-152. [6] 乐杰.妇产科学[M].7版.北京:人民卫生出版,2008:278-288. [7] 任秀宝,于津浦. 肿瘤免疫治疗疗效评价的新标准[J].中国肿瘤生物治疗杂志,2011,18(4):351-354. [8] BAERT T, FERRERO A, SEHOULI J, et al. The systemic treatment of recurrent ovarian cancer revisited[J].Ann Oncol,2021,32(6):710-725. [9] KURNIT K C, FLEMING G F, LENGYEL E. Updates and new options in advanced epithelial ovarian cancer treatment[J].Obstet Gynecol,2021,137(1):108-121. [10] CHEN W C, HUANG H J, CHANG T C, et al. Dose-dense chemotherapy with weekly paclitaxel and 3-weekly carboplatin for recurrent ovarian cancer[J].Taiwan J Obstet Gynecol,2020,59(1):21-27. [11] 武加利,方延宁,李红. DC-CIK细胞免疫治疗联合化疗对复发性卵巢癌患者免疫功能、凝血功能及肿瘤干细胞标志物的影响[J].海南医学院学报,2017,23(23):3282-3285. [12] 毛小刚,江红,刘韵,等. 贝伐单抗、紫杉醇、卡帕三者联合治疗复发性卵巢癌的疗效分析[J].实用癌症杂志,2017,32(8):1370-1372. [13] 郜晓,宋丽丽,朱凯,等. 贝伐单抗联合白蛋白结合型紫杉醇治疗铂类耐药的复发性卵巢癌的临床效果观察[J].中国综合临床,2018,34(3):209-214. [14] 李晓兰,赵骏达,马俊旗. 贝伐单抗联合白蛋白结合型紫杉醇对铂类耐药复发转移性卵巢癌患者的疗效及其免疫功能的影响[J].药物生物技术,2021,28(5):491-495. [15] 孙自琴,程贤英. 伊立替康联合贝伐单抗治疗铂类耐药复发性卵巢癌疗效观察[J].医学临床研究,2020,37(12):1782-1785. [16] 李化,周莉. Ⅲ、Ⅳ期复发性卵巢癌患者行贝伐单抗联合TP方案的临床疗效[J].中国老年学杂志,2020,40(24):5196-5198.
2024, Vol. 41 
